Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
59
VRDN Quote, Financials, Valuation and Earnings
Last price:
$32.33
Seasonality move
:
-12.78%
Day range:
$31.26 - $32.66
52-week range:
$9.90 - $34.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
36.90x
P/B ratio:
9.78x
Volume:
2.1M
Avg. volume:
1.5M
1-year change:
75.31%
Market cap:
$3.1B
Revenue:
$302K
EPS (TTM):
-$3.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
$15.8M | -$1.00 | -80.15% | -2.95% | $41.82 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
AVTR
Avantor, Inc.
|
$1.6B | $0.22 | -0.43% | 115.56% | $13.04 |
|
IMVT
Immunovant, Inc.
|
-- | -$0.70 | -- | -10.01% | $40.31 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
OFIX
Orthofix Medical, Inc.
|
$218.7M | $0.44 | 1.41% | -97.73% | $22.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
$32.17 | $41.82 | $3.1B | -- | $0.00 | 0% | 36.90x |
|
ADMA
ADMA Biologics, Inc.
|
$17.40 | $25.67 | $4.1B | 20.43x | $0.00 | 0% | 8.76x |
|
AVTR
Avantor, Inc.
|
$12.24 | $13.04 | $8.3B | 10.97x | $0.00 | 0% | 1.27x |
|
IMVT
Immunovant, Inc.
|
$26.18 | $40.31 | $4.6B | -- | $0.00 | 0% | -- |
|
MRKR
Marker Therapeutics, Inc.
|
$2.04 | $7.87 | $34M | -- | $0.00 | 0% | 5.53x |
|
OFIX
Orthofix Medical, Inc.
|
$13.83 | $22.80 | $547.7M | -- | $0.00 | 0% | 0.66x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
4.52% | 1.767 | 1.21% | 11.06x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.305 | 2.38% | 3.53x |
|
AVTR
Avantor, Inc.
|
40.92% | 1.212 | 45.33% | 0.90x |
|
IMVT
Immunovant, Inc.
|
-- | 1.621 | -- | 8.28x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 1.778 | -- | 5.66x |
|
OFIX
Orthofix Medical, Inc.
|
31.61% | 0.203 | 35.34% | 1.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
$70.3M | -$40M | -46.01% | -47.79% | -56.7% | -$84.7M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
AVTR
Avantor, Inc.
|
$526.5M | $138.4M | -0.81% | -1.4% | 8.52% | $171.7M |
|
IMVT
Immunovant, Inc.
|
-$105K | -$131.8M | -88.09% | -88.1% | -- | -$102.5M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
OFIX
Orthofix Medical, Inc.
|
$145.4M | -$17.5M | -17.83% | -24.94% | -8.5% | $2.5M |
Viridian Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VRDN or ADMA?
ADMA Biologics, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of 27.14%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About VRDN or ADMA?
Viridian Therapeutics, Inc. has a consensus price target of $41.82, signalling upside risk potential of 30.01%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 47.51%. Given that ADMA Biologics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is VRDN or ADMA More Risky?
Viridian Therapeutics, Inc. has a beta of 0.945, which suggesting that the stock is 5.488% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.393%.
-
Which is a Better Dividend Stock VRDN or ADMA?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or ADMA?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 20.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.90x versus 8.76x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.36.90x -- $70.6M -$34.6M ADMAADMA Biologics, Inc.8.76x 20.43x $134.2M $36.4M
-
Which has Higher Returns VRDN or AVTR?
Avantor, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -43.84%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Avantor, Inc.'s return on equity of -1.4%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M AVTRAvantor, Inc.32.42% -$1.04 $9.4B -
What do Analysts Say About VRDN or AVTR?
Viridian Therapeutics, Inc. has a consensus price target of $41.82, signalling upside risk potential of 30.01%. On the other hand Avantor, Inc. has an analysts' consensus of $13.04 which suggests that it could grow by 6.5%. Given that Viridian Therapeutics, Inc. has higher upside potential than Avantor, Inc., analysts believe Viridian Therapeutics, Inc. is more attractive than Avantor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 AVTRAvantor, Inc.3 14 1 -
Is VRDN or AVTR More Risky?
Viridian Therapeutics, Inc. has a beta of 0.945, which suggesting that the stock is 5.488% less volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.414%.
-
Which is a Better Dividend Stock VRDN or AVTR?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or AVTR?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Viridian Therapeutics, Inc.'s net income of -$34.6M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.90x versus 1.27x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.36.90x -- $70.6M -$34.6M AVTRAvantor, Inc.1.27x 10.97x $1.6B -$711.8M
-
Which has Higher Returns VRDN or IMVT?
Immunovant, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of --. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Immunovant, Inc.'s return on equity of -88.1%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M IMVTImmunovant, Inc.-- -$0.73 $519.7M -
What do Analysts Say About VRDN or IMVT?
Viridian Therapeutics, Inc. has a consensus price target of $41.82, signalling upside risk potential of 30.01%. On the other hand Immunovant, Inc. has an analysts' consensus of $40.31 which suggests that it could grow by 53.98%. Given that Immunovant, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Immunovant, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 IMVTImmunovant, Inc.11 4 0 -
Is VRDN or IMVT More Risky?
Viridian Therapeutics, Inc. has a beta of 0.945, which suggesting that the stock is 5.488% less volatile than S&P 500. In comparison Immunovant, Inc. has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.758%.
-
Which is a Better Dividend Stock VRDN or IMVT?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunovant, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Immunovant, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or IMVT?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Immunovant, Inc. quarterly revenues of --. Viridian Therapeutics, Inc.'s net income of -$34.6M is higher than Immunovant, Inc.'s net income of -$126.5M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Immunovant, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.90x versus -- for Immunovant, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.36.90x -- $70.6M -$34.6M IMVTImmunovant, Inc.-- -- -- -$126.5M
-
Which has Higher Returns VRDN or MRKR?
Marker Therapeutics, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -162.11%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About VRDN or MRKR?
Viridian Therapeutics, Inc. has a consensus price target of $41.82, signalling upside risk potential of 30.01%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 285.62%. Given that Marker Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is VRDN or MRKR More Risky?
Viridian Therapeutics, Inc. has a beta of 0.945, which suggesting that the stock is 5.488% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.371, suggesting its more volatile than the S&P 500 by 37.092%.
-
Which is a Better Dividend Stock VRDN or MRKR?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or MRKR?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.90x versus 5.53x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.36.90x -- $70.6M -$34.6M MRKRMarker Therapeutics, Inc.5.53x -- $1.2M -$2M
-
Which has Higher Returns VRDN or OFIX?
Orthofix Medical, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -11.09%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Orthofix Medical, Inc.'s return on equity of -24.94%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M OFIXOrthofix Medical, Inc.70.71% -$0.57 $647M -
What do Analysts Say About VRDN or OFIX?
Viridian Therapeutics, Inc. has a consensus price target of $41.82, signalling upside risk potential of 30.01%. On the other hand Orthofix Medical, Inc. has an analysts' consensus of $22.80 which suggests that it could grow by 64.86%. Given that Orthofix Medical, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Orthofix Medical, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 OFIXOrthofix Medical, Inc.3 1 0 -
Is VRDN or OFIX More Risky?
Viridian Therapeutics, Inc. has a beta of 0.945, which suggesting that the stock is 5.488% less volatile than S&P 500. In comparison Orthofix Medical, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.22%.
-
Which is a Better Dividend Stock VRDN or OFIX?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Orthofix Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or OFIX?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are smaller than Orthofix Medical, Inc. quarterly revenues of $205.6M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Orthofix Medical, Inc.'s net income of -$22.8M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Orthofix Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.90x versus 0.66x for Orthofix Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.36.90x -- $70.6M -$34.6M OFIXOrthofix Medical, Inc.0.66x -- $205.6M -$22.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is down 2.18% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 6.98% over the past day.
Sell
24
INSP alert for Jan 23
Inspire Medical Systems, Inc. [INSP] is down 0.01% over the past day.
